Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

SAB Biotherapeutics (SABSW) Leases (2020 - 2025)

SAB Biotherapeutics' Leases history spans 6 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Leases fell 27.35% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, down 27.35%, while the annual FY2025 figure was $2.6 million, 27.35% down from the prior year.
  • Leases reached $2.6 million in Q4 2025 per SABSW's latest filing, down from $2.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $4.0 million in Q1 2022 to a low of $730583.0 in Q2 2023.
  • Average Leases over 5 years is $2.7 million, with a median of $3.2 million recorded in 2025.
  • Peak YoY movement for Leases: tumbled 81.49% in 2023, then surged 279.93% in 2024.
  • A 5-year view of Leases shows it stood at $2.6 million in 2021, then plummeted by 54.42% to $1.2 million in 2022, then surged by 207.84% to $3.7 million in 2023, then fell by 2.37% to $3.6 million in 2024, then dropped by 27.35% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Leases are $2.6 million (Q4 2025), $2.8 million (Q3 2025), and $3.5 million (Q2 2025).